Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results

Author:

Hanafusa NorioORCID,Isoai Ayako,Ishihara Tomoaki,Inoue Tetsuya,Ishitani Ken,Utsugisawa Taiju,Yamaka Toshihiko,Ito Tetsuya,Sugiyama Hiroshi,Arakawa Atsushi,Yamada Yosuke,Itano Yasuo,Onodera Hirokazu,Kobayashi Ryosuke,Torii Naoko,Numata Toyoko,Kashiwabara Taihei,Matsuno Yoshihiro,Kato Michio

Funder

Asahi Kasei Medical

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference25 articles.

1. Autologous and Homologous Transfusion of Human Ascitic Fluid;HA Davis;J Clin Invest,1939

2. Ascites (in Japanese);T Oda;Jpn J Clin Exp Med,1974

3. Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites;T Ito;Int J Clin Oncol,2015

4. The present state of cell-free and concentrated ascites reinfusion therapy (CART) for refractory ascites: Focusing on the clinical factors affecting fever as an adverse effect of CART (in Japanese);S Takamatsu;Kan Tan Sui,2003

5. Single center experience of cell-free and concentrated ascites reinfusion therapy in malignancy related ascites;T Ito;Ther Apher Dial,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3